Navigation Links
Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
Date:11/13/2012

SAN DIEGO, Nov. 13, 2012 /PRNewswire/ -- CanChew BioTechnologies Inc, a portfolio company of Medical Marijuana Inc. (OTC: MJNA), announces that this week marks the final three days to register for the market trial of CanChew gum.  Qualifying participants will receive a minimum of a 30-day free trial sample of the CBD-based CanChew gum in exchange for their product feedback.  The only cost involved will be a nominal shipping charge of $4.95 for delivery of the product. 

While the company has been researching distribution partnerships for over-the-counter sales of the CanChew gum product, preparations for clinical trials have been underway in Europe and are slated to begin during 2013.  U.S. clinical trials should begin shortly thereafter.  Successful trials and new drug application may eventually lead to a European and/or U.S. pharmaceutical product with substantiated medical claims. Over the counter sales of CanChew gum are expected to begin in the first quarter of 2013. 

Ted Caligiuri, President and CEO of Medical Marijuana Inc. comments: "We are pleased with the interest in our CanChew market survey and free product trial and eagerly anticipate positive feedback from clients."

The gum contains high concentrations of CBD hemp oil and its raw ingredients are derived from the operations of PhytoSphere systems, an MJNA portfolio company.  MJNA anticipates selling these products through the Internet, as well portfolio company Red Dice Holdings national distribution platform. Currently, Red Dice Holdings distributes a variety of CBD Hemp oil products in over 500 retail locations throughout Colorado, Arizona, California and New Mexico.

Please visit this link to sign up for the market trial: http://www.canchewbiotech.com/component/users/?view=registration

About CanChew
CanChew® is a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of cannabis/cannabinoid(s) based pharmaceuticals. The delivery of these medications via the oral mucosa provides for rapid and near complete absorption directly into the systemic circulation. This leads to rapid onset of effects and increased bioavailability. Pre-systemic metabolism is thus avoided. This system of delivery offers clearly improved economic opportunities compared to alternative drug delivery routes. 

About Medical Marijuana, Inc.                                                                                               Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.

Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.

For more information, please visit the company's website at: www.MedicalMarijuanaInc.com

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.

Corporate Contact:

Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc 
Investor Relations Contact:
Stuart T. Smith
SmallCapVoice.Com, Inc.
P. 512-267-2430
F. 512-267-2530
Email: ssmith@smallcapvoice.com
Skype: SmallCapVoice.com
AIM: SmallCapVoice7


'/>"/>
SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at MEDICA
2. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
3. Dukes Ralph Snyderman, M.D. Joins SenGenix as Senior Medical Advisor and Board Member
4. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
5. Medical Device Study Presents Detailed View of Key Budget and Staffing Metrics for Marketing Groups
6. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
7. Sony Medical Division Teams with Wills Eye Institute to Bring "Expert" Panel of Ophthalmologists to AAO 2012 Convention
8. STD Med Inc. Receives ANVISA Registration for Class III Medical Devices in Brazil
9. Mount Sinai Medical Center 1st in Tri-State Area to Discharge Patient without Human Heart
10. Concord Medical Announces Change to Third Quarter Financial Results Date to November 20, 2012
11. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):